• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatic oncology. >Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?
【24h】

Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

机译：肝细胞癌经动脉疗法的进展：新技术能否带来更好的结果？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Conventional transarterial chemoembolization (c-TACE) was validated in 2002 for intermediate stage hepatocellular carcinoma (HCC). Recent improvements in overall survival after c-TACE in HCC is linked to both better patient selection, and improvement in treatment technologies: catheter, image guidance and new drug delivery platforms. Drug eluting beads (DEBs) demonstrated a benefit over c-TACE in pharmacokinetic studies; however, two randomized studies comparing c-TACE and DEB-TACE demonstrated no benefit of DEB-TACE in response rate or overall survival. Delivery platforms loaded with yttrium-90 deliver selective internal radiation therapy, which opens a new field of therapy for HCC. Future improvement in intra-arterial therapies will include resorbable loadable embolic material, new emulsion used for c-TACE and platforms releasing multikinase inhibitors.
机译：传统的经动脉化学栓塞术（c-TACE）于2002年通过了中期肝细胞癌（HCC）的验证。肝癌中c-TACE术后近期总体生存的改善与更好的患者选择以及治疗技术的改善有关：导管，图像引导和新药物递送平台。在药代动力学研究中，药物洗脱珠（DEBs）优于c-TACE。但是，两项比较c-TACE和DEB-TACE的随机研究表明，DEB-TACE在缓解率或总生存率方面无益处。装有yttrium-90的输送平台可提供选择性的内部放射疗法，这为HCC开辟了新的治疗领域。动脉内治疗的未来改进将包括可吸收的可加载栓塞材料，用于c-TACE的新乳液以及释放多激酶抑制剂的平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号